A Leizorovicz, V Siguret… - Thrombosis Research, 2011 - Elsevier The trial was stopped prematurely due to a difference in mortality favoring the UFH group (11.5 vs. 6.3%; p = 0.035). Rates of clinically relevant bleedings by day 90 were similar in the tinzaparin (11.9%) and UFH (11.9%) groups, as were rates of confirmed recurrent venous ... Cited by 1 - Related articles - All 3 versions
K Sritharan, T Lane, K Duong, IJ Franklin… - …, 2011 - phleb.rsmjournals.com Method: Patients referred to a vascular surgery clinic at Charing Cross Hospital, for management of their CVD, were invited to complete a validated questionnaire relating to disease-specific quality of life (Aberdeen Varicose Veins Questionnaire [AVVQ]) and depressive symptoms ...
FF van Doormaal, AT Cohen, BL Davidson… - Thrombosis and …, 2011 - schattauer.de Standard treatment with heparin followed by vitamin K antagonists is frequently complicated by bleeding and recurrent venous thromboembolism (VTE) in cancer patients with VTE. To compare the efficacy, safety and overall survival of long-term idraparinux treatment to standard ... Cited by 7 - Related articles - All 5 versions
C Esmon - Annual Review of Physiology, 2011 - annualreviews.org The mechanisms of vascular control of thrombotic events remain unclear. The vasculature possesses essential anticoagulant factors that regulate coagulation. Because the endothelium-to-blood ratios are much higher in the microcirculation, it is likely that stasis contributes to ... Cited by 1 - Related articles - All 2 versions
EVS Faustino, KA Lawson, V Northrup… - Critical care …, 2011 - journals.lww.com This publication was made possible in part by CTSA Grant Number UL1 RR024139 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility ... Cited by 1 - Related articles - All 5 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
